Nathan Hedin

Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas

John M. Pagel, Nathan Hedin, Krishnan Subbiah et al. · Blood · 2003 · 101 citations

Medicine, Hematology, Oncology +16

A Genetically Engineered Anti-CD45 Single-Chain Antibody-Streptavidin Fusion Protein for Pretargeted Radioimmunotherapy of Hematologic Malignancies

Yukang Lin, John M. Pagel, Donald B. Axworthy et al. · Cancer Research · 2006 · 64 citations

Life Sciences, Hematology, Immunology +17

Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas

John M. Pagel, Yukang Lin, Nathan Hedin et al. · Blood · 2006 · 47 citations · Full text

Pharmacy, Immunology, Oncology +17

Evaluation of CD20, CD22, and HLA-DR Targeting for Radioimmunotherapy of B-Cell Lymphomas

John M. Pagel, Anastasia Pantelias, Nathan Hedin et al. · Cancer Research · 2007 · 43 citations

Medicine, Hematology, Oncology +14

Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism

Ajay K. Gopal, John M. Pagel, Nathan Hedin et al. · Blood · 2003 · 35 citations · Full text

Medicine, Oncology, Pharmacology +11